BioSpace News Archive

Scholar Rock today announced the company will present new data that highlight the development of its highly selective, context-dependent TGFβ1 antibody.

Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2022, reaffirmed guidance, and provided a business update.

Adverum Bio today announced new data from the OPTIC study treating wet age-related macular degeneration (wet AMD) during the American Society of Retina Specialists (ASRS) 2022 Annual Meeting.

Pulnovo Medical Limited, a globally recognized device pioneer in the treatment for cardiopulmonary diseases, today announced that it has successfully concluded the first Pre-Sub meeting with the U.S. Food and Drug Administration (“FDA”) for its Pulmonary Artery Denervation (PADN) Global Trial.

Dr Roffey brings over 20 years of drug discovery experience gained in the pharmaceutical and biotechnology sectors, where he contributed to the development of multiple candidate drugs and late-stage clinical assets. He has extensive experience in a variety of therapeutic areas, including central nervous system, oncology and metabolic disorders across a range of therapeutic modalities.

Neurophth Therapeutics, Inc., (“Neurophth”) today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has granted a Breakthrough Therapy Designation (BTD) to the Company’s leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber’s hereditary optic neuropathy (LHON) associated with mtND4 mutation.

Alzheimer disease is a neurodegenerative disorder which is characterized by significant cognitive deficits, behavioral changes, sleep disorders, and loss of functional autonomy.

Parkinson’s disease is a most commonly diagnosed age related neurodegenerative disorder, which affects the normal movements of body due to genetic and environmental factors.

Today, the Honourable Jean-Yves Duclos, Minister of Health, and the Honourable Filomena Tassi, Minister of Public Services and Procurement, announced that the Government of Canada has signed a new contract with GlaxoSmithKline (GSK) to support sustained influenza pandemic readiness.

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram.